APLS
Income statement / Annual
Last year (2024), Apellis Pharmaceuticals, Inc.'s total revenue was $709.95 M,
an increase of 79.01% from the previous year.
In 2024, Apellis Pharmaceuticals, Inc.'s net income was -$197.88 M.
See Apellis Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$709.95 M |
$396.59 M |
$75.42 M |
$66.56 M |
$250.65 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$117.72 M
|
$58.51 M
|
$5.64 M
|
$5.20 M
|
$25.05 M
|
$288.02 M
|
$127.92 M
|
$50.77 M
|
$0.00
|
$0.00
|
| Gross Profit |
$592.23 M
|
$338.08 M
|
$69.79 M
|
$61.36 M
|
$225.60 M
|
-$288.02 M
|
-$127.92 M
|
-$50.77 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.83
|
0.85
|
0.93
|
0.92
|
0.9
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$327.57 M
|
$354.39 M
|
$387.24 M
|
$420.87 M
|
$299.92 M
|
$220.97 M
|
$105.29 M
|
$40.30 M
|
$22.98 M
|
$13.73 M
|
| General & Administrative Expenses |
$0.00
|
$500.82 M
|
$277.16 M
|
$176.77 M
|
$139.40 M
|
$67.05 M
|
$22.64 M
|
$10.46 M
|
$4.30 M
|
$6.36 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$501.05 M
|
$500.82 M
|
$277.16 M
|
$176.77 M
|
$139.40 M
|
$67.05 M
|
$22.64 M
|
$10.46 M
|
$4.30 M
|
$6.36 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$288,000.00
|
$1.36 M
|
-$501,000.00
|
-$175,314.00
|
-$110,758.00
|
$11,542.00
|
$157,705.00
|
$6,284.00
|
| Operating Expenses |
$828.62 M
|
$855.20 M
|
$664.40 M
|
$597.64 M
|
$439.32 M
|
$288.02 M
|
$127.92 M
|
$50.77 M
|
$27.28 M
|
$20.09 M
|
| Cost And Expenses |
$946.35 M
|
$913.71 M
|
$670.04 M
|
$602.84 M
|
$464.37 M
|
$288.02 M
|
$127.92 M
|
$50.77 M
|
$27.28 M
|
$20.09 M
|
| Interest Income |
$12.77 M
|
$20.93 M
|
$8.91 M
|
$418,000.00
|
$4.16 M
|
$5.11 M
|
$2.96 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$40.39 M
|
$29.58 M
|
$32.63 M
|
$13.24 M
|
$29.94 M
|
$5.28 M
|
$2.51 M
|
$96,915.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.80 M
|
$1.70 M
|
$1.49 M
|
$1.49 M
|
$859,000.00
|
$595,449.00
|
$127.93 M
|
$11,935.00
|
$27.28 M
|
$52.97 M
|
| EBITDA |
-$236.39 M |
-$495.21 M |
-$617.39 M |
-$731.27 M |
-$312.23 M |
-$298.83 M |
$0.00 |
-$50.90 M |
$157,710.00 |
$6.40 M |
| EBITDA Ratio |
-0.33
|
-1.25
|
-7.75
|
-8.01
|
-0.84
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.33
|
-1.3
|
-7.88
|
-8.06
|
-0.85
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$39.68 M
|
-$9.38 M
|
-$56.89 M
|
-$209.73 M
|
-$129.30 M
|
-$16.69 M
|
$422,806.00
|
-$239,065.00
|
$157,705.00
|
$57,137.00
|
| Income Before Tax |
-$196.72 M
|
-$526.50 M
|
-$651.50 M
|
-$746.00 M
|
-$343.03 M
|
-$304.71 M
|
-$127.50 M
|
-$51.01 M
|
-$27.12 M
|
-$46.52 M
|
| Income Before Tax Ratio |
-0.28
|
-1.33
|
-8.64
|
-11.21
|
-1.37
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.16 M
|
$2.13 M
|
$669,000.00
|
$352,000.00
|
$1.85 M
|
$5.11 M
|
-$533,324.00
|
$250,607.00
|
-$27.28 M
|
-$26.54 M
|
| Net Income |
-$197.88 M
|
-$528.63 M
|
-$652.17 M
|
-$746.35 M
|
-$344.87 M
|
-$309.82 M
|
-$127.50 M
|
-$51.01 M
|
-$27.12 M
|
-$46.52 M
|
| Net Income Ratio |
-0.28
|
-1.33
|
-8.65
|
-11.21
|
-1.38
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.6 |
-4.45 |
-6.15 |
-8.84 |
-4.59 |
-4.98 |
-2.34 |
-3.68 |
-1.5 |
-2.57 |
| EPS Diluted |
-1.6 |
-4.45 |
-6.15 |
-8.84 |
-4.59 |
-4.98 |
-2.34 |
-3.68 |
-1.5 |
-2.57 |
| Weighted Average Shares Out |
$123.90 M
|
$118.68 M
|
$106.11 M
|
$84.42 M
|
$75.16 M
|
$62.23 M
|
$54.40 M
|
$13.87 M
|
$18.09 M
|
$18.09 M
|
| Weighted Average Shares Out Diluted |
$123.90 M
|
$118.68 M
|
$106.11 M
|
$84.42 M
|
$75.16 M
|
$62.23 M
|
$54.40 M
|
$13.87 M
|
$18.09 M
|
$18.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
